The 5th Ophthalmic Drug Delivery Summit addresses innovations in ophthalmic drug delivery methods and devices, focusing on achieving minimally invasive, sustained-release solutions for treating eye diseases.
Key Topics
Suprachoroidal Delivery in Gene Therapy to Capitalize on Ocular Anatomy
Overcoming Hurdles in Ophthalmic Clinical Trial Design to Spearhead Development
The State of Play for Ophthalmic Drug Delivery to the Retina
Advancing Retinal Therapy With Sustained Release Implants to Reduce Treatment Frequency
The Journey of Genentech’s Susvimo Port Delivery System’s from Challenges to FDA Reapproval
Advancements in Large Volume Formulations & High Viscosity Injectable Drug Delivery
Drug Delivery Mechanics for Extended Release Implants
Establishing Robust Clinical Trial Design to Overcome Past Failings
Overcoming Inflammatory Responses to Maximize Therapeutic Effect
The Evolving Landscape of Regulatory Approvals for Combination Products
Navigating the Safety Landscape of Novel Drug Delivery
Advancing Drug Formulations & Combinations to Achieve Sustained Release
Advancing Targeted, Compartmentalized & Long-Acting Depot Delivery: Synergistic Combination of Particulate Formulation & Suprachoroidal Route of Administration
Enhancing Ocular Drug Delivery Through Combined Microparticles, Nanoparticles & Hydrogels
Mastering Suprachoroidal Delivery to Increase Distribution & Durability
Expanding the Potential of the Suprachoroidal Space in Retinal Therapy
Considering Non-Invasive Administration of Medications for Retinal Diseases : a Mechanism of Action Perspective
Comparing of Existing Ophthalmic Models Approaches to Supercharge Development
Utilizing Preclinical & Computational Models for Predicting Human Ophthalmic Drug Behavior
Delivery Effective Cell & Gene Therapies to the Eye to Halt Vision Loss
Optimizing Current Suprachoroidal & Subretinal Delivery of AAV Gene Therapies
Enhancing Cell & Gene Therapies With Advanced Hydrogel Platforms
Disease Indication & Endpoint Selection for Ophthalmic Gene Therapy Trials to Unlock Optimal Results
Innovations with Topical & Oral Medications & the Path to Regulatory Success
Considering Systemic Administration of PPARalpha Agonist for the Treatment of Diabetic Retinopathy & AMD
